Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Upstream Bio (UPB) over the last 1 years, with Sep 2025 value amounting to $8.1 million.

  • Upstream Bio's Gains from Investment Securities rose 30.44% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 30.44%. This contributed to the annual value of $6.5 million for FY2024, which is 55.79% up from last year.
  • Latest data reveals that Upstream Bio reported Gains from Investment Securities of $8.1 million as of Q3 2025, which was down 1.38% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Upstream Bio's Gains from Investment Securities ranged from a high of $8.3 million in Q2 2025 and a low of $3,000 during Q4 2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $7.9 million (2025), whereas its average is $6.1 million.
  • Data for Upstream Bio's Gains from Investment Securities shows a peak YoY skyrocketed of 30.44% (in 2025) over the last 5 years.
  • Over the past 3 years, Upstream Bio's Gains from Investment Securities (Quarterly) stood at $3,000 in 2023, then reached $6.2 million in 2024, then soared by 30.44% to $8.1 million in 2025.
  • Its last three reported values are $8.1 million in Q3 2025, $8.3 million for Q2 2025, and $7.9 million during Q1 2025.